Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis
- 1 March 2017
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 152 (4), 911-912
- https://doi.org/10.1053/j.gastro.2016.12.021
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antiviralsJournal of Hepatology, 2016
- Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohortsJournal of Hepatology, 2016
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyJournal of Hepatology, 2016
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosisJournal of Hepatology, 2016
- Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without CirrhosisGastroenterology, 2015
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006